S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:HCM

HUTCHMED Stock Forecast, Price & News

$31.51
-1.39 (-4.22%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.20
$33.87
50-Day Range
$29.42
$37.30
52-Week Range
$23.67
$43.94
Volume
618,284 shs
Average Volume
217,502 shs
Market Capitalization
$5.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.93
30 days | 90 days | 365 days | Advanced Chart
Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.


HUTCHMED logo

About HUTCHMED

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.

Headlines

HUTCHMED (NASDAQ:HCM) Shares Gap Up to $34.03
November 30, 2021 |  americanbankingnews.com
HUTCHMED (NASDAQ:HCM) Trading Down 5.9%
November 29, 2021 |  americanbankingnews.com
HUTCHMED (NASDAQ:HCM) Stock Price Up 7.1%
November 26, 2021 |  americanbankingnews.com
HUTCHMED (NASDAQ:HCM) Shares Gap Up to $30.72
November 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCM
Employees
1,280
Year Founded
N/A

Sales & Book Value

Annual Sales
$227.98 million
Book Value
$3.89 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$5.45 billion
Optionable
Not Optionable

Company Calendar

Today
12/04/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

732nd out of 1,390 stocks

Pharmaceutical Preparations Industry

345th out of 668 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












HUTCHMED (NASDAQ:HCM) Frequently Asked Questions

Is HUTCHMED a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HUTCHMED stock.
View analyst ratings for HUTCHMED
or view top-rated stocks.

How has HUTCHMED's stock been impacted by COVID-19?

HUTCHMED's stock was trading at $23.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HCM shares have increased by 36.8% and is now trading at $31.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for HCM?

4 brokers have issued twelve-month target prices for HUTCHMED's shares. Their forecasts range from $45.00 to $52.00. On average, they anticipate HUTCHMED's stock price to reach $47.67 in the next year. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for HUTCHMED
or view top-rated stocks among Wall Street analysts.

Who are HUTCHMED's key executives?

HUTCHMED's management team includes the following people:
  • Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 69, Pay $80k)
  • Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 55, Pay $1.41M)
  • Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 54, Pay $788.96k)
  • Dr. Wei-Guo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 64, Pay $1.21M)
  • Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, Solicito, Company Sec. & Non-Exec. Director (Age 69, Pay $70k)
  • Mr. Mark Lee, Sr. VP of Corp. Fin. & Devel. (Age 44)
  • Mr. Charles Nixon, Group Gen. Counsel
  • Mr. Andrew Shih, Sr. VP of HR - Organization & Leadership Devel.
  • Dr. May Wang, Sr. VP of Bus. Devel. & Strategic Alliances (Age 58)
  • Mr. Hong Chen, Chief Commercial Officer - China, GM - Hutchison Sinopharm & GM - Hutchison Healthcare (Age 51)

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

(HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a number of institutional and retail investors. Top institutional shareholders include M&G Investment Management Ltd. (2.53%), Sands Capital Management LLC (2.42%), General Atlantic L.P. (2.31%), BlackRock Inc. (2.00%), Schroder Investment Management Group (1.75%) and Wellington Management Group LLP (1.60%).

Which major investors are selling HUTCHMED stock?

HCM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Allianz Asset Management GmbH, Millennium Management LLC, Assenagon Asset Management S.A., M&G Investment Management Ltd., AIA Group Ltd, FIL Ltd, and Renaissance Technologies LLC.

Which major investors are buying HUTCHMED stock?

HCM stock was purchased by a variety of institutional investors in the last quarter, including General Atlantic L.P., Schroder Investment Management Group, BlackRock Inc., Goldman Sachs Group Inc., Zeal Asset Management Ltd, York Capital Management Global Advisors LLC, Bellevue Group AG, and Sands Capital Management LLC.

How do I buy shares of HUTCHMED?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $31.51.

How much money does HUTCHMED make?

HUTCHMED has a market capitalization of $5.45 billion and generates $227.98 million in revenue each year.

How many employees does HUTCHMED have?

HUTCHMED employs 1,280 workers across the globe.

What is HUTCHMED's official website?

The official website for HUTCHMED is www.chi-med.com.

Where are HUTCHMED's headquarters?

How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2121-3888, via email at [email protected], or via fax at 852-2128-1778.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.